logo
Tesla's Robotaxi Hype Fuels Bullish Price Targets to $500

Tesla's Robotaxi Hype Fuels Bullish Price Targets to $500

Globe and Mail17 hours ago
Considering how much pain investors of Tesla Inc (NASDAQ: TSLA) had to endure during the first quarter of the year, there are perhaps not many on Wall Street who thought they'd manage to gain the better part of 50% in less than three months.
However, that's exactly what they've done, largely thanks to CEO Elon Musk's stepping back from White House duties, increased hype around their Robotaxi launch, and a sense that the worst-case scenario has already been priced into the stock.
As they continue to consolidate with mostly sideways action since the first week of June, it's a good time to take stock of what the summer might look like for the shares of the automotive giant.
While the stock has undoubtedly received its fair share of negative headlines in recent weeks, there are still many reasons to like Tesla for the long term.
Getting Involved in Tesla
For investors on the sidelines weighing up an entry or an exit, two very interesting and unusual things took place last week that should be closely watched: Tesla received both a pair of Sell ratings and a pair of Buy ratings. For a stock that the bulls and the bears have closely fought over, this hardly clarifies things for investors trying to make a call.
But upon close examination, there's actually a pretty solid opportunity opening up here, and these calls might even make it easier. Let's jump in and take a closer look.
Bears Reiterate Their Case
Starting with the bearish updates, which came first at the start of last week, we saw the teams from both Guggenheim and UBS Group reiterate their Sell ratings on the stock. Unconvinced by Tesla's nearly 50% gain in just a few weeks, the analysts there were happy to overlook the potential upside from the company's much-awaited Robotaxi launch, which took place on Monday.
With its price-to-earnings ratio around the 175 mark, Guggenheim's Ronald Jewsikow also sounded the alarm on Tesla's valuation, which has repeatedly been flagged as a reason to be cautious.
Potential 50% Downside
Even though Tesla's shares have always shown signs of not caring about the underlying PE, Jewsikow's price target of $175 must have raised a few eyebrows. Considering that Tesla closed out last week trading just above $320, it implies that a loss of close to 50% is around the corner.
This would result in shares trading back at 52-week lows, which is an extreme forecast for someone who didn't provide much justification beyond stating that the company's fundamentals are "deteriorating at an alarming rate."
It's true that Tesla's post-April recovery seems to have run out of steam, and it might well be worrying that shares have failed to kick on since their peak in late May, but the stock has still been setting higher highs throughout June, all in the face of their most recent earnings report which was indeed one of their worst updates to their fundamentals in quite some time.
But the fact that the stock has remained consistently higher since then suggests the market doesn't care quite as much about that as the bears might want it to.
Bulls See Big Upside
On the other hand, by the end of last week, Tesla had received two fresh bullish updates: one from Canaccord Genuity Group and one from Benchmark. The latter boosted its price target to $475, just marginally below Tesla's street-high price target of $500, which came from Wedbush earlier this month.
The teams were unanimous in their optimism around the company's Robotaxi launch, which they see as a key milestone in Tesla's journey to offer the most cost-effective driverless cars.
Echoing much of what his peers have shared in recent months, Benchmark's Mickey Legg wrote that "in our view, the company is undergoing an evolution from a trailblazing vehicle OEM to a high-tech automation and robotics company with unmatched domestic manufacturing scale."
As Tesla stock has shown time and again, it has a stronger tendency to be bought for these kinds of reasons than to be sold due to valuation concerns, as flagged by Guggenheim. The fact that the stock is up close to 50% since missing analyst expectations in its May earnings report by a wide margin tells you a lot about how Tesla investors view the longer-term opportunity.
As July approaches, it's expected that Tesla will keep generating mixed opinions, as it has historically. However, the ticker tells the story, and so far, at least, it's telling us that the stock wants to, and will, go higher.
Where Should You Invest $1,000 Right Now?
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Will AbbVie's Acquisition Spree Aid Pipeline Growth?
Will AbbVie's Acquisition Spree Aid Pipeline Growth?

Globe and Mail

time9 minutes ago

  • Globe and Mail

Will AbbVie's Acquisition Spree Aid Pipeline Growth?

AbbVie ABBV has been actively ramping up its deal-making efforts lately, thereby strengthening its pipeline. While immunology remains its core area, the company is also signing some early-stage deals across various other therapeutic areas, including oncology and neuroscience. Earlier this week, AbbVie signed a definitive agreement to acquire privately held biotech Capstan Therapeutics for a total deal value of nearly $2.1 billion. The transaction, expected to be completed in the third quarter, will add Capstan's lead asset, CPTX2309 — a potential first-in-class in vivo tLNP anti-CD19 CAR-T therapy — to its immunology pipeline. The acquisition will also add Capstan's proprietary tLNP platform technology, CellSeeker, which helps deliver RNA, like mRNA, to engineer specific cell types inside the body. Since the beginning of last year, the company has signed over 20 early-stage deals, including promising technologies and innovative mechanisms that can elevate the standard of care across various therapeutic areas. Earlier this year, AbbVie acquired rights to develop a long-acting amylin analog for the treatment of obesity from Denmark's Gubra, marking its foray into the obesity space. It also plans to invest further in obesity. Among some recent larger deals, AbbVie acquired ImmunoGen, which added the ovarian cancer drug Elahere and neuroscience drugmaker Cerevel Therapeutics last year. These acquisitions have not only broadened AbbVie's therapeutic footprint but also diversified its pipeline across multiple modalities. The augmented pipeline now includes next-generation immunology candidates, bispecifics, antibody-drug conjugates and innovative therapies for neuropsychiatric and neurodegenerative disorders. We believe ABBV will continue pursuing such deals to further grow its pipeline. Focus on M&A in 2025 While broader macroeconomic concerns, including Trump-era tariffs and leadership shifts at the FDA, have weighed on deal-making this year, Big Pharma continues to pursue strategic assets in key growth areas. Last month, Eli Lilly LLY announced its intent to acquire cardiology-focused Verve Therapeutics in a deal valued at up to $1.3 billion. This transaction, which is also expected to close in the third quarter, will mark LLY's third targeted M&A deal this year. Earlier in January, it signed a $2.5 billion deal for Scorpion Therapeutics' experimental oncology drug. In May, Lilly agreed to acquire SiteOne Therapeutics for $1 billion to strengthen its neuroscience pipeline. Such deals suggest that LLY's M&A strategy is selective, focusing on long-term strength across therapeutic areas beyond its dominant presence in obesity. In June, Sanofi SNY announced a $9.5 billion acquisition of Blueprint Medicines to strengthen its immunology pipeline and reduce reliance on the blockbuster drug Dupixent. Through this transaction, SNY intends to add Ayvakit — an inhibitor of KIT and PDGFRA proteins with growing commercial traction — and several early-stage pipeline assets focused on systemic mastocytosis (SM). Recently, Sanofi completed the acquisition of an investigational bispecific antibody targeting autoimmune diseases from California-based Dren Bio and also agreed to acquire neurology-focused Vigil Neuroscience in a deal valued at around $470 million. ABBV's Price Performance, Valuation and Estimates Shares of AbbVie have outperformed the industry year to date, as seen in the chart below. From a valuation standpoint, AbbVie is not very cheap. Based on the price/earnings (P/E) ratio, the company's shares currently trade at 14.42 times forward earnings, slightly lower than its industry's average of 14.86. The stock is cheaper than some other large drugmakers, such as Eli Lilly and Novo Nordisk, but priced much higher than most other large drugmakers. The stock is also trading above its five-year mean of 12.46. The Zacks Consensus Estimate for 2025 EPS has risen from $12.26 to $12.28, while that for 2026 has remained consistent at $14.06 over the past 60 days. AbbVie currently has a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Zacks' Research Chief Names "Stock Most Likely to Double" Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest. This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Sanofi (SNY): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report This article originally published on Zacks Investment Research (

Elon Musk wants to create a new political party. Building rockets may be easier
Elon Musk wants to create a new political party. Building rockets may be easier

CTV News

time10 minutes ago

  • CTV News

Elon Musk wants to create a new political party. Building rockets may be easier

(Elon Musk looks on during a news conference with U.S. President Donald Trump in the Oval Office on May 30. Allison Robbert/AFP/Getty Images via CNN Newsource) Elon Musk has started multiple successful companies that have accomplished incredible technological feats. His latest ambition may be significantly more difficult to achieve: starting a new American political party for the masses. Citing his disappointment in U.S. President Donald Trump and his massively expensive domestic policy bill, Musk said he would form the 'America party' the day after the 'Big, Beautiful Bill' passes, if Congress approves it. Musk has called Democrats and Republicans the 'uniparty' because government deficits have risen dramatically under administrations and Congresses controlled by both parties. He says he wants to build a fiscally conservative party that reins in spending – although he's presented few other details of what the party's platform might be. Experts in campaign finance and political science say there's a reason no third party has ever truly successfully challenged America's two-party system: It is financially and legally difficult to create a new party, and voters and candidates are hesitant to join. 'Third-party movements in the US have generally arisen out of some sort of set of deep-seated grievances,' Emory University political science professor Alan Abramowitz told CNN. 'It was not just some wealthy person who's decided they wanted to start a third party.' It's not clear how much if any preparation has been done to stand up the party. A spokesperson for Musk's political action committee, America PAC, declined to comment. A senior White House official brushed off Musk's criticism of the bill. 'No one really cares what he says anymore,' the source said. Two Republicans close to the White House said that it was also unclear how Musk's threats might play out in the midterm elections. 'Of course, members don't want to be primaried,' one of the sources said. 'It's unclear if he's actually going to get involved. A few weeks ago he apologized and called Trump.' Musk may be the richest person on Earth, but he could also encounter some financial resistance himself. Former DOGE adviser and Trump supporter James Fishback said he is launching his own super PAC to counter Musk's money in congressional races. Fishback, who runs an investment firm, said he will provide $1 million in initial funding to the super PAC, which will be called FSD PAC, an abbreviation for Full Support for Donald. He told CNN that the super PAC will work to back Trump's agenda 'and against anyone who threatens to sabotage that agenda,' including Musk. Legal hurdles American political parties are governed by laws and rules not just from the Federal Election Commission but also from the states, including around which parties can appear on ballots. 'The system is sort of set up to almost make it impossible for third parties to be successful,' Abramowitz said. Funding a new party has its own hurdles. The McCain-Feingold Bipartisan Campaign Reform Act of 2022 set strict limits on donations to political parties. The current limit is just under $450,000 spread across different party purposes. Musk would need thousands of co-donors to help him fund his party, said Lee Goodman, an attorney and former chair of the FEC. 'One very wealthy individual cannot capitalize a new national political party, the way he might start a business, because of federal contribution limits,' Goodman told CNN. 'The prospect of a wealthy founder seed funding a national party to participate in federal elections around the country is not feasible in the current regulatory system.' Bradley Smith, another former FEC chair and who is now a law professor at Capital University Law School, said there are some ways around the current regulations. 'There is some case law suggesting that some of the organizational activities of a party and starting a party right can be funded with larger contributions, until it actually qualifies for party status under the election commission regulations,' Smith said, but he noted it's complex and difficult to do. 'You can fund super PACs all you want. But you can't fund a political party, as a strange part of American law,' he added. Super PACs are not legally allowed to coordinate spending with parties or candidates, although previous candidates have tested these limits, as nothing prohibits coordination when the information is shared publicly. 'Coordination has, in fact, become commonplace,' the nonpartisan Campaign Legal Center has said. Then there's getting on the actual ballots. States have different rules, such as requiring a certain number of signatures. 'It would take years and might require changes in laws around the country that currently favor two major political parties,' Goodman noted Political hurdles Beyond the legal and logistical hurdles, there's convincing candidates to join and voters to cast their ballots for them. Despite varying approval levels, party loyalties remain strong, Abramowitz said, especially among Republicans, who have coalesced around Trump. 'The biggest obstacle is just that it's very difficult to convince people to vote for a third-party candidate because the argument is always 'you're wasting your vote. You're voting for someone who has no chance of winning elections,'' Abramowitz said. Candidates may also be wary. Democrats are unlikely to run under the America Party because 'Democrats hate Elon Musk,' Abramowitz said. And Republicans 'have clearly shown that they're much more attached to Donald Trump than they are to Elon Musk.' Republicans highly approve of Trump, according to CNN Chief Data Analyst Harry Enten's aggregation of available polling data. Some 90 precent of Republicans approve of Trump's performance thus far in this presidency, and he is doing better in approval ratings five months into the presidency than former Republican presidents. And in 96 per cent of the 2024 primary races where Trump endorsed, those candidates won. If creating a new political party proves too difficult, Musk could still hold a lot of sway through his super PAC, to which he can send unlimited funds. That PAC can then support independent candidates, who could also have an easier time getting on ballots. 'Independent spending, individually or via a super PAC, remains the most legal and practical mechanism for a wealthy individual to have a say in national politics,' Goodman said. Article written by Hadas Gold, CNN CNN's Kristen Holmes and Fredreka Schouten contributed reporting.

Chuck E. Cheese is opening arcades for adults
Chuck E. Cheese is opening arcades for adults

CTV News

time12 minutes ago

  • CTV News

Chuck E. Cheese is opening arcades for adults

Chuck E. Cheese isn't just for the kids anymore. The arcade chain is opening a spin-off aimed at adults, called 'Chuck's Arcade,' which the company describes as a 'modern-day love letter to the games and people who made Chuck E. Cheese great.' Similar to the kiddie version, Chuck's Arcade has a mix of nostalgic arcade games, like Donkey Kong and Mortal Kombat; and newer titles such as Halo and Connect Four Hoops. Plus, each arcade is 'overseen' by one of the chain's iconic animatronic characters, including Chuck E. Cheese himself or other characters from his Munch's Make Believe Band. Ten are open so far at malls across the United States, with arcades in St. Petersburg, Florida; Tulsa, Oklahoma; El Paso, Texas; and St. Louis. Each location looks different, decorated with original artwork that celebrates the brand's past, according to a release. Of course, there will also be prizes for adults to win and arcades will have 'old-school merch' available for purchase. Some arcades will serve food, with the Kansas City location having a pizzeria that also serves a small selection of beer and wine, a spokesperson told CNN. David McKillips, CEO of Chuck. E. Cheese, said that the spin-off is a 'natural evolution' for the company following the remodel of its 500 locations and sees it as an 'opportunity to extend our arcade legacy into new formats that engage both lifelong fans and a new generation through a curated mix of retro classics and cutting-edge experiences.' The company's expansion comes five years after it filed for bankruptcy during the height of the Covid-19 pandemic. Chuck E. Cheese spent $350 million in remodels over the past few years as well as introducing new pricing tiers to attract budget-focused families. The launch of Chuck's Arcade comes amid troubles for its chief rival Dave & Buster's. The latter is publicly traded and recently reported a 9.4 per cent decline in same-store sales, with its new management trashing 'ill-advised changes' implemented by its previous leadership that included too many adjustments at once. Article written by Jordan Valinsky, CNN

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store